A2 Bio shared updates on its Tmod™ CAR T-cell clinical programs at the SITC 2024 annual meeting, focusing on enhancing participant diversity and enrollment in the BASECAMP-1 prescreening study.
A2 Bio presented updates on its Tmod™ CAR T-cell therapy platform at SITC 2024, which utilizes a dual-receptor system to target and kill tumor cells while protecting normal tissues.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.